Patients with DEPDC5 mutations [12], associated with mTOR pathway dysregulation, may benefit from targeted treatments such as mTOR inhibitors (e.g., everolimus), which have shown promise in related epilepsy syndromes. The gene discussed is DEPDC5; the disease is epilepsy syndrome.